Swee Lay Thein
National Heart, Lung, and Blood Institute (NHLBI) · King's College Hospital NHS Trust
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
15
all conditions, ClinicalTrials.gov
NIH grants tied to them
11
NIH RePORTER
Trial papers
14
PubMed author-name match
Trials
Studies that name Swee Lay Thein as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:56 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07566494 · Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · recruiting · Sickle Cell Disease, Hemolytic Anemia · principal investigator
- Ph1NCT05904093 · Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · recruiting · Sickle Cell Disorders, Sickle Cell Disease, Hemoglobin S · principal investigator
- N/ANCT05675436 · Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · active not recruiting · Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain · principal investigator
- N/ANCT05604547 · Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients With Sickle Cell Disease (SCD)National Heart, Lung, and Blood Institute (NHLBI) · completed · SCD · principal investigator
- Ph1/Ph2NCT04610866 · Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of MitapivatNational Heart, Lung, and Blood Institute (NHLBI) · active not recruiting · Sickle Cell Disease, Hemolytic Anemia · principal investigator
- Early Ph1NCT04000165 · A Dose-Finding Study of AG-348 in Sickle Cell DiseaseNational Institutes of Health Clinical Center (CC) · completed · Sickle Cell Disease · principal investigator
- N/ANCT03685721 · Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · recruiting · Sickle Cell, PKLR Variants, Adenosine Triphosphate Activities · principal investigator
- N/ANCT03572036 · Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary HypertensionNational Heart, Lung, and Blood Institute (NHLBI) · completed · Pulmonary Hypertension, Sickle Cell Disease · principal investigator
- N/ANCT03049475 · Pathophysiology of Acute Pain in Patients With Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Disease · principal investigator
- Ph2NCT01925001 · Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle CrisisSangart · withdrawn · Anemia, Sickle Cell, Sickle Cell Anemia, Sickle Cell Disease · principal investigator
- N/ANCT01441141 · Genetics and Pain Severity in Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · completed · Genotype, Pain, Genetic Variation · principal investigator
- N/ANCT00367523 · Pulmonary Hypertension in Patients With Sickle Cell Disease in NigeriaNational Heart, Lung, and Blood Institute (NHLBI) · completed · Secondary Pulmonary Arterial Hypertension, Sickle Cell Disease, Pulmonary Hypertension · principal investigator
- N/ANCT00081523 · Natural History of Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · recruiting · Pain Crisis · principal investigator
- N/ANCT00047996 · Blood Collection for Research Related to Certain Diseases Involving Blood VesselsNational Heart, Lung, and Blood Institute (NHLBI) · enrolling by invitation · Sickle Cell Disease · principal investigator
- N/ANCT00011648 · Secondary Pulmonary Hypertension in Adults With Sickle Cell AnemiaNational Heart, Lung, and Blood Institute (NHLBI) · completed · Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with stable sickle cell diseaseZIAHL006284 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2024 to 2025 · $684,323 awarded in 2025Same name and institution; not confirmed by an ID
- A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell DiseaseZIAHL006282 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2024 to 2025 · $228,108 awarded in 2025Same name and institution; not confirmed by an ID
- A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell diseaseZIAHL006239 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2019 to 2025 · $45,622 awarded in 2025Same name and institution; not confirmed by an ID
- Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell diseaseZIAHL006266 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2021 to 2025 · $456,215 awarded in 2025Same name and institution; not confirmed by an ID
- Exploring Near Infrared Spectroscopy (NIRS) technologies for assessment of muscle physiology, tissue oxygenation, and blood flow in patients with Sickle Cell Disease (SCDZIAHL006283 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2023 to 2025 · $45,622 awarded in 2025Same name and institution; not confirmed by an ID
- Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell DiseaseZIAHL006240 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2019 to 2025 · $684,323 awarded in 2025Same name and institution; not confirmed by an ID
- Human Specimen Collection to Support Basic and Clinical ResearchZIAHL006241 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2024 to 2025 · $775,566 awarded in 2025Same name and institution; not confirmed by an ID
- Observational Study Investigating the Mechanistic Effects of Mitapivat in Subjects with Sickle Cell DiseaseZIAHL006296 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2024 to 2025 · $684,323 awarded in 2025Same name and institution; not confirmed by an ID
- Studies of the Natural History of Sickle Cell DiseaseZIAHL006233 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2017 to 2025 · $958,053 awarded in 2025Same name and institution; not confirmed by an ID
- Pathophysiology of Acute Pain in Patients with Sickle Cell DiseaseZIAHL006232 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2017 to 2020 · $954,373 awarded in 2020Same name and institution; not confirmed by an ID
- A QTL for fetal hemoglobin and F cells on chromosome 8qR01HL069259 · NHLBI · KING'S COLLEGE LONDON · fiscal years 2001 to 2003 · $250,000 awarded in 2003Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:56 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.Haematologica · 2010229 citationsRCR 7.2
- 118 citationsRCR 7.0
- 66 citationsRCR 2.0
- Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant.Br J Haematol · 201956 citationsRCR 3.2
- Genetic determinants of haemolysis in sickle cell anaemia.Br J Haematol · 201345 citationsRCR 1.4
- A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.Br J Haematol · 201332 citationsRCR 1.0
- Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.Eur J Haematol · 201123 citationsRCR 0.8
- Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.Lancet Haematol · 202519 citationsRCR 6.2
- Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease.Haematologica · 202415 citationsRCR 2.5
- Effects of co-existing α-thalassaemia in sickle cell disease on hydroxycarbamide therapy and circulating nucleic acids.Br J Haematol · 201211 citationsRCR 0.5